Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amcenestrant - Sanofi

Next Previous
Search
Drug Profile

Amcenestrant - Sanofi

Alternative Names: SAR 439859; SERD '859

Latest Information Update: 24 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi
  • Developer Alliance Foundation Trials; Breast International Group; European Organisation for Research and Treatment of Cancer; Sanofi
  • Class 2 ring heterocyclic compounds; Antineoplastics; Carboxylic acids; Chlorobenzenes; Ethers; Fluorinated hydrocarbons; Phenols; Pyrrolidines; Small molecules
  • Mechanism of Action Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 26 Dec 2024 Sanofi terminates Phase-I clinical trials in Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in Japan (PO) due to sponsors decision to end the study prematurely (NCT03816839)
  • 08 Nov 2024 Sanofi terminates phase-I/II AMEERA-1 trial in Breast cancer (Late-stage disease, Second-line therapy or greater, Monotherapy, Metastatic disease, Combination therapy) in Canada, Belgium, Czechia, Italy, Poland, Portugal, Spain, France, USA and United Kingdom (PO) (NCT03284957),
  • 19 Oct 2022 Adverse events and efficacy data from a phase II AMEERA-3 trial in Breast cancer presented at the 47th European Society for Medical Oncology Congress (ESMO 2022)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top